Skip to main content
OpenTrials
Completed

NCT Number: NCT02391688

Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail

Phenotyping is an approach largely used for the evaluation of the activity of cytochromes and transporters in vivo. It consists of the administration of probe substances metabolised by a specific cytochrome or transported by P-glycoprotein (P-gp) for example, followed by the determination of a metabolic ratio or the evaluation of the plasmatic or urinary concentrations of the probe substances. The administration of a cocktail containing several probe substances allows the simultaneous evaluation of the activity of several cytochromes and P-gp in a single test.

When a cocktail approach is used it is important to make sure that no drug-drug interactions occur between the probes within the cocktail. The validation of the lack of interactions, which is the aim of the study, consists of demonstrating that there is no difference in the pharmacokinetic parameters and/or metabolic ratios when a probe is administered alone or as part of the cocktail. The Geneva cocktail consists of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam and fexofenadine for the simultaneous phenotyping of CYP1A2, CYP2B6, CYP2C9, CAP2C19, CYP2D6, CYP3A4 and P-gp, respectively.

Probe and metabolite concentrations will be measured in capillary blood using a dried blood spot (DBS) analysis. To further facilitate sampling, a new simple device will be used to ensure the precision of capillary blood collection.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Centre de Recherche Clinique, HUG, Rue Gabrielle Perret-Gentil 4

Geneva, 1211, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers aged from 18 to 60 years
  • BMI between 18 and 27
  • Understanding of French language and able to give a written inform consent.

Exclusion criteria

  • smoker
  • pregnant women
  • taking drugs which alter cytochrome P450 (CYP) activity
  • renal or hepatic impairment
  • medical history of chronic alcoholism or abuse of psychoactive drugs
  • liver transplantation
  • sensitivity to any of the drugs used
  • Alteration of hepatic tests, more than 2x normal (aspartate transaminase >100U/L ; alanine transaminase >100 units/L ; gamma-glutamyl transferase >80 units/L ; bilirubin >50µmol/L)
  • Presenting genetic polymorphism of poor CYP2C9, CYP2C19, CYP2D6 metabolizer

Treatment and study plan

Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam

Drug

bupropion

Drug

fexofenadine

Drug

Primary outcomes

  1. Area under the capillary blood concentration-time curve (AUC) of caffeine

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D

    Comparison of caffeine AUC when treatment A or D is administered

  2. Area under the capillary blood concentration-time curve (AUC) of dextromethorphan

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D

    Comparison of dextromethorphan AUC when treatment A or D is administered

  3. Area under the capillary blood concentration-time curve (AUC) of flurbiprofen

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D

    Comparison of flurbiprofen AUC when treatment A or D is administered

  4. Area under the capillary blood concentration-time curve (AUC) of midazolam

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D

    Comparison of midazolam AUC when treatment A or D is administered

  5. Area under the capillary blood concentration-time curve (AUC) of omeprazole

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D

    Comparison of omeprazole AUC when treatment A or D is administered

  6. Area under the capillary blood concentration-time curve (AUC) of fexofenadine

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment B or D

    Comparison of fexofenadine AUC when treatment B or D is administered

  7. Area under the capillary blood concentration-time curve (AUC) of bupropion

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post treatment C or D

    Comparison of bupropion AUC when treatment C or D is administered

Secondary outcomes

  1. Metabolic ratio (MR) of paraxanthine blood concentration /caffeine blood concentration

    Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D

    Comparison of paraxanthine/caffeine MRs between treatment A and D

  2. Metabolic ratio (MR) of dextrorphan blood concentration /dextromethorphan blood concentration

    Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D

    Comparison of dextrorphan/dextromethorphan MRs between treatment A and D

  3. Metabolic ratio (MR) of 4-hydroxyflurbiprofen blood concentration /flurbiprofen blood concentration

    Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D

    Comparison of 4-hydroxyflurbiprofen/flurbiprofen MRs between treatment A and D

  4. Metabolic ratio (MR) of 1-hydroxymidazolam blood concentration /midazolam blood concentration

    Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D

    Comparison of 1-hydroxymidazolam/midazolam MRs between treatment A and D

  5. Metabolic ratio (MR) of 5-hydroxyomeprazole blood concentration /omeprazole blood concentration

    Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D

    Comparison of 5-hydroxyomeprazole/omeprazole MRs between treatment A and D

  6. Metabolic ratio (MR) of 4-hydroxybupropion blood concentration /bupropion blood concentration

    Time frame: 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post treatment C or D

    Comparison of 4-hydroxybupropion/bupropion MRs between treatment C and D

  7. Number of adverse events

    Time frame: at each drug administration day

Other outcomes

  1. Correlation of drug concentrations (ng/ml) in DBS obtained with two sampling techniques for all administered drugs

    Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A, B, C and D

Sponsors and collaborators

Lead sponsor

Jules Desmeules

Other

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Mar 18, 2015
Registry last updated
Feb 7, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.